0001562180-20-000669.txt : 20200129 0001562180-20-000669.hdr.sgml : 20200129 20200129161322 ACCESSION NUMBER: 0001562180-20-000669 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200128 FILED AS OF DATE: 20200129 DATE AS OF CHANGE: 20200129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Firuta Paul E CENTRAL INDEX KEY: 0001602727 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33095 FILM NUMBER: 20558301 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE, THIRD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACHILLION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070336 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 203-624-7000 MAIL ADDRESS: STREET 1: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-01-28 true 0001070336 ACHILLION PHARMACEUTICALS INC ACHN 0001602727 Firuta Paul E C/O ACHILLION PHARMACEUTICALS, INC. 1777 SENTRY PARKWAY W, BLDG 14, STE 200 BLUE BELL PA 19422 false true false false EVP, Chief Commercial Officer Stock Options (Right to buy) 3.32 2020-01-28 4 D false 400000.00 D 2028-09-11 Common Stock 400000.00 0.00 D Stock Options (Right to buy) 2.18 2020-01-28 4 D false 200000.00 D 2029-01-23 Common Stock 200000.00 0.00 D Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. /s/ Keri Lantz, attorney-in-fact 2020-01-29